United Therapeutics wins Federal Circuit appeal in Liquidia patent litigation; Yutrepia approval delayed

UNITED THERAPEUTICS Corp

Federal Circuit affirmed Liquidia's Yutrepia infringes United Therapeutics' '793 patent; FDA approval blocked until patent expires May 14, 2027.
Court confirmed Liquidia would induce infringement by marketing Yutrepia; all '793 claims held valid over invalidity challenges.
Federal Circuit also affirmed certain claims of U.S. Patent No. 9,593,066 are either invalid or not infringed by Liquidia.
Both parties may request rehearing; PTAB IPR decision finding '793 unpatentable is on appeal by United Therapeutics.
District court order barring FDA final approval remains unless infringed claims are found invalid after exhaustion of appeals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.